Health Care • Biotechnology: Pharmaceutical Preparations
$1.51 ▼ -0.39
(-20.53%)
MKT CAP: $1.9M • VOL: 83.0K
52W L $1 52W H $14
ROARABLE / RQD
D- • 35/100
PIOTROSKI
3 / 9
MTNB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $1.1M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.0M | -$24.6M | -$23.8M |
| Operating Margin % | — | — | -80.0% |
| Net Income (GAAP) | -$10.3M | -$24.3M | -$22.9M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$7.0M | -$15.9M | -$15.3M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$7.0M | -$15.9M | -$15.3M |
| FCF Margin % | — | — | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $4.0M | $7.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $4.8M | $7.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MTNB.